m. tuberculosis h37rv

BM635 is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 hydrochloride is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

BM635 mesylate is an MmpL3 inhibitor with outstanding anti-mycobacterial activity (MIC50: 0.12 μM against M. tuberculosis H37Rv).

Thiacetazone (Diazam) 是一种氨基硫脲抗结核剂，也是一种具有口服活性抗生素。它具有抗菌作用，可抑制结核分枝杆菌 H37Rv 的生长，MIC 值为 0.1 μg/mL。

Q203 (Telacebec)是一种中氮杂吡啶酰胺。 在培养基中抑制结核分枝杆菌H37Rv 活性的MIC50值为2.7 nM。

NITD-349 是MmpL3的抑制剂，它对毒性结核分枝杆菌 H37Rv 显示出高效的抗分枝杆菌活性，MIC50 为 23 nM。

sCNH240(2-Fluoro-N-[3-(3-thienyl)-5-isoxazolyl]benzenesulfonamide)是一种潜在的选择性 Rv1625c/Cya 激活剂，具有良好的细胞渗透性和口服活性，在胆固醇补充的7H12培养基中对结核分枝杆菌（Mtb）H37Rv 株的IC90=1.24 µM，对 CYP2C19，CYP2C9 和hERG 通道具有抑制作用。

Pks13-IN-1 (Compound 44) 是一种口服有效的 Mycobacterium tuberculosis 聚酮合酶 13 (Pks13) 抑制剂。它对结核分枝杆菌 H37Rv 菌株的抑制浓度 (MIC) 为 0.07 μM。在小鼠模型中，Pks13-IN-1 展示了抗菌活性。

JNJ-2901 是一种 M. tuberculosis cytochrome bc1:aa3 抑制剂，能够降低 M. tuberculosis H37Rv-ΔcydAB 急性和慢性小鼠感染模型中的细菌载量。JNJ-2901 可用于结核病 (TB) 的研究。

Antitubercular agent-42(19) 是一种选择性的 fatty acyl-AMP ligase (FAAL) 抑制剂，其对 M. tuberculosis H37Rv 的 MIC90 为 1.4 µg/mL。Antitubercular agent-42 展现出抑制结核杆菌的活性。

Mtb-IN-7 (compound R7) 是一种MAO-A/MAO-B抑制剂，其IC50值超过40 μM。对结核杆菌M. tuberculosis H37Rv表现出抑菌活性，MIC值为2.01 μM。

Antibacterialagent 228 (Compound 8) 能抑制分枝杆菌核糖体，其对Mycobacterium smegmatis的IC50为2.31 μM，并对M. tuberculosis H37Rv [野生型和 Δ1258c 突变型的MIC分别为2和0.25 μg/mL]、M. abscessus ATCC 19977 [野生型和 Δ2780c 突变型的MIC均为8 μg/mL]以及M. smegmatis (MIC=8 μg/mL) 展示了抗菌活性。

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg/ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg/kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg/kg to 2.5 mg/kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

Tuberculosis inhibitor 3 (compound 2i)是一种高效和具有口服生物利用度的抗结核药物，对药敏和耐药结核分枝杆菌，M. tuberculosis H37RV与MDR-TB，体外抗药活性均为MIC < 0.016 μg/mL。

Polyketide synthase 13-IN-3 (compound 41) is a potent inhibitor of polyketide synthase 13, demonstrating a minimum inhibitory concentration (MIC) range of 0.0625-0.125 μg/mL against the M. tuberculosis strain H37Rv.

GSK2200150A 是一种通过高通量筛选活动确定的抗结核剂，对 H37Rv 的 MIC 是 0.38 μM。

Steviolbioside (CCRIS-6025) 是一种存在于甜菊叶中的罕见甜味剂。它对几种人类癌细胞有抑制作用，对乳腺癌具有潜在的研究价值。

TBAJ-587 是一种抗结核药物，在 MABA 和 LORA 试验中抑制 M.tb 菌株 H37Rv 的生长，MIC90 分别为 0.006 和 <0.02 µg/mL。它对 M. tuberculosis 具有更有效的活性，并且在 TB 动物模型中具有更好的功效。

Antituberculosis agent-2 (Compound 8d) 是一种针对耐多药结核病和药物敏感结核病均有效的抗结核剂。Antituberculosis agent-2 在小鼠和人类中显示出良好的微粒稳定性，具有低细胞毒性和可接受的口服生物利用度。Antituberculosis agent-2 具有抗结核活性。Antituberculosis agent-2 对结核分枝杆菌 H37Rv、13946 和 14862 的 MIC 值分别为0.454、1.757 和 1.644 μg/mL。

Antitubercular agent-15 (Compound 5n) 是一种抗结核剂， 对肺成纤维细胞和巨噬细胞具有低细胞毒性。Antitubercular agent-15 对结核分枝杆菌 H37Rv、CF16、CF61、CF76、CF152 和 CF161 的 MIC90值分别为 0.73、7.69、9.38、18.80、7.53 和 7.31 μg/mL。

Antitubercular agent-21 (Compound 15) 是具有低细胞毒性的抗结核剂。Antitubercular agent-21 对 M. tuberculosisH37Rv 的 MIC 值为 0.4 μg/mL。然而，Antitubercular agent-21 对其他微生物，如革兰氏阳性菌、革兰氏阴性菌或真菌，表现出较低的生物活性。

Antitubercular agent-17 (Compound 8a) 是一种抗结核剂，对 M. tuberculosisH37Rv、Spec. 192、Spec 210 和 Spec. 800 的 MIC 值分别为 2、2、2 和 128 μg/ml。Antitubercular agent-17 表现出高选择性的抗分支杆菌效果。

Antitubercular agent-18 (Compound 9a) 为抗结核剂，对M. tuberculosisH37Rv、Spec. 192、Spec 210 及 Spec. 800 的最小抑制浓度(MIC)值依次为2、2、2 及128 μg/ml，展现出对分支杆菌的高选择性抗菌活性。

Antituberculosis agent-1 (Compound 8a) 是一种抗结核剂，对 M. tuberculosisH37Rv 的 MIC 值为 3.84 μg/mL。